GHGuardant Health, Inc.
Services-Medical Laboratories
- Revenue
- $982M
- 33% YoY
- Operating margin
- -44.5%
- 26% YoY
- EBITDA
- −$398M
- 0.9% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $449M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired17% of revenueOver 10% of revenue
- Payouts exceed cash flowClear-24% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear4% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $374M | $450M | $564M | $739M | $982M | 33% |
| Operating income | −$411M | −$544M | −$565M | −$444M | −$437M | 1.4% |
| Net income | −$385M | −$655M | −$479M | −$436M | −$416M | 4.6% |
| Operating cash flow | −$209M | −$309M | −$325M | −$240M | −$185M | 23% |
| Capex | $75M | $77M | $20M | $35M | $48M | 38% |
| Stock-based comp | $151M | $95M | $91M | $140M | $166M | 18% |
| Buybacks | — | — | $0 | $0 | $45M |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $3M · 12
- Net
- −$3M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 79 | 125 |
| FY2024 | — | — | 24 | 93 |
| FY2023 | — | — | 21 | 94 |
| FY2022 | — | — | 21 | 90 |
| FY2021 | — | — | 78 | 100 |